| Record ID | marc_loc_2016/BooksAll.2016.part34.utf8:110172859:1901 |
| Source | Library of Congress |
| Download Link | /show-records/marc_loc_2016/BooksAll.2016.part34.utf8:110172859:1901?format=raw |
LEADER: 01901cam a22003614a 4500
001 2007008032
003 DLC
005 20090226085345.0
008 070223s2007 njua b 001 0 eng
010 $a 2007008032
020 $a9780470073735 (cloth : alk. paper)
035 $a(DNLM)101300038
040 $aDNLM/DLC$cDLC$dDLC
042 $apcc
050 00 $aRS189$b.T85 2007
060 10 $aQV 771$bT948n 2007
082 00 $a615/.19$222
100 1 $aTurner, J. Rick.
245 10 $aNew drug development :$bdesign, methodology, and analysis /$cJ. Rick Turner.
260 $aHoboken, N.J. :$bWiley-Interscience,$cc2007.
300 $axxi, 270 p. :$bill. ;$c25 cm.
490 0 $aStatistics in practice
504 $aIncludes bibliographical references (p. [245]-257) and index.
505 0 $aNew drug development -- The regulatory environment for new drug development -- Drug discovery -- Nonclinical research -- Design and methodology in clinical trials -- Statistical analysis -- Statistical significance : employment of hypothesis testing -- Clinical significance : employment of confidence intervals -- Sample-size estimation -- Safety assessment in clinical trials -- Efficacy assessment in clinical trials -- Pharmaceutical and biopharmaceutical drug manufacturing -- Postmarketing surveillance and evidence-based medicine -- Unifying themes and concluding comments.
650 0 $aDrug development.
650 0 $aPharmacy.
650 12 $aClinical Trials.
650 12 $aPharmaceutical Preparations$xchemical synthesis.
650 22 $aDrug Industry$xmethods.
650 22 $aStatistics.
856 41 $3Table of contents only$uhttp://www.loc.gov/catdir/toc/ecip0712/2007008032.html
856 42 $3Publisher description$uhttp://www.loc.gov/catdir/enhancements/fy0739/2007008032-d.html
856 42 $3Contributor biographical information$uhttp://www.loc.gov/catdir/enhancements/fy0739/2007008032-b.html